Literature DB >> 20695017

Disrupted SOX10 regulation of GJC2 transcription causes Pelizaeus-Merzbacher-like disease.

Hitoshi Osaka1, Haruka Hamanoue, Ryoko Yamamoto, Atsuo Nezu, Megumi Sasaki, Hirotomo Saitsu, Kenji Kurosawa, Hiroko Shimbo, Naomichi Matsumoto, Ken Inoue.   

Abstract

Mutations in the gap junction protein gamma-2 gene, GJC2, cause a central hypomyelinating disorder; Pelizaeus-Merzbacher-like disease (PMLD; MIM311601). Using a homozygosity mapping and positional candidate gene approach, we identified a homozygous mutation (c.-167A>G) within the GJC2 promoter at a potent SOX10 binding site in a patient with mild PMLD. Functionally, this mutation completely abolished the SOX10 binding and attenuated GJC2 promoter activity. These findings suggest not only that the SOX10-to-GJC2 transcriptional dysregulation is a cause of PMLD, but also that GJC2 may be in part responsible for the central hypomyelination caused by SOX10 mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695017     DOI: 10.1002/ana.22022

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

Review 1.  Brain connexins in demyelinating diseases: therapeutic potential of glial targets.

Authors:  Maria Luisa Cotrina; Maiken Nedergaard
Journal:  Brain Res       Date:  2012-07-10       Impact factor: 3.252

2.  High frequency of GJA12/GJC2 mutations in Turkish patients with Pelizaeus-Merzbacher disease.

Authors:  B Bilir; Z Yapici; C Yalcinkaya; I Baris; C M B Carvalho; M Bartnik; B Ozes; M Eraksoy; J R Lupski; E Battaloglu
Journal:  Clin Genet       Date:  2012-02-20       Impact factor: 4.438

3.  Differential Sox10 genomic occupancy in myelinating glia.

Authors:  Camila Lopez-Anido; Guannan Sun; Matthias Koenning; Rajini Srinivasan; Holly A Hung; Ben Emery; Sunduz Keles; John Svaren
Journal:  Glia       Date:  2015-05-14       Impact factor: 7.452

Review 4.  Gap junctions in inherited human disorders of the central nervous system.

Authors:  Charles K Abrams; Steven S Scherer
Journal:  Biochim Biophys Acta       Date:  2011-08-16

Review 5.  Gap junction communication in myelinating glia.

Authors:  Anna Nualart-Marti; Carles Solsona; R Douglas Fields
Journal:  Biochim Biophys Acta       Date:  2012-02-03

6.  A new mutation in GJC2 associated with subclinical leukodystrophy.

Authors:  Charles K Abrams; Steven S Scherer; Rafael Flores-Obando; Mona M Freidin; Sarah Wong; Eleonora Lamantea; Laura Farina; Vidmer Scaioli; Davide Pareyson; Ettore Salsano
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

7.  GJC2 promoter mutations causing Pelizaeus-Merzbacher-like disease.

Authors:  Leo Gotoh; Ken Inoue; Guy Helman; Sara Mora; Kiran Maski; Janet S Soul; Miriam Bloom; Sarah H Evans; Yu-Ichi Goto; Ljubica Caldovic; Grace M Hobson; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2013-12-16       Impact factor: 4.797

8.  Expanded spectrum of Pelizaeus-Merzbacher-like disease: literature revision and description of a novel GJC2 mutation in an unusually severe form.

Authors:  Roberta Biancheri; Camillo Rosano; Laura Denegri; Eleonora Lamantea; Francesca Pinto; Federica Lanza; Mariasavina Severino; Mirella Filocamo
Journal:  Eur J Hum Genet       Date:  2012-06-06       Impact factor: 4.246

9.  SNP array-based whole genome homozygosity mapping as the first step to a molecular diagnosis in patients with Charcot-Marie-Tooth disease.

Authors:  Carina Fischer; Slave Trajanoski; Lea Papić; Christian Windpassinger; Günther Bernert; Michael Freilinger; Maria Schabhüttl; Mine Arslan-Kirchner; Poupak Javaher-Haghighi; Barbara Plecko; Jan Senderek; Christian Rauscher; Wolfgang N Löscher; Thomas R Pieber; Andreas R Janecke; Michaela Auer-Grumbach
Journal:  J Neurol       Date:  2011-09-04       Impact factor: 4.849

10.  Exome sequencing & homozygosity mapping for identification of genetic aetiology for spastic ataxia in a consanguineous family.

Authors:  Ashwin Dalal; Aneek Das Bhowmik; Divya Agarwal; Shubha R Phadke
Journal:  Indian J Med Res       Date:  2015-08       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.